Human-derived monoclonal antibodies and recombinant antigens
Ended Awarded Last action
- Contract number
- HT942525FE048
- Awardee
-
Mapp Biopharmaceutical, Inc. UEI M9V9QTHR1H28
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $60,500
Award facts
- Contract value 100% obligated
- $60,500.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a $60.5k firm fixed-price delivery order to Mapp Biopharmaceutical, Inc. for the development of human-derived monoclonal antibodies and recombinant antigens. The contract carries an ultimate completion date of February 25, 2026, and will be performed at Mapp's facility in San Diego, California. This award was made without set-aside designation and represents a continuation of the Defense Health Agency's procurement efforts in medical countermeasures and immunotherapies.
Mapp Biopharmaceutical is a San Diego-based biotechnology company with established expertise in antibody-based therapeutics and medical countermeasures against infectious diseases and biological threats. The company has a substantial history of federal contracting, having received over $1.2 billion in prior awards from agencies including the Office of the Assistant Secretary for Preparedness and Response and the Defense Health Agency for development of therapeutics targeting threats such as Ebola, Sudan, and Marburg viruses. This delivery order aligns with the Defense Health Agency's strategic focus on developing advanced biological medical countermeasures to support military medical preparedness and national health security objectives.
Quick answers
Who was awarded contract HT942525FE048?
HT942525FE048 was awarded to Mapp Biopharmaceutical, Inc. by Defense Health Agency (Department of Defense) on September 19, 2025.
How much is contract HT942525FE048 worth?
The government has obligated $60,500 on HT942525FE048.
Is contract HT942525FE048 an order under another contract?
Yes. HT942525FE048 is a delivery order under HT942525D0009, an indefinite delivery contract.
Was contract HT942525FE048 competed?
The extent of competition for HT942525FE048 was not competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award